CING
NASDAQ HealthcareCingulate Inc. - Common Stock
Biotechnology
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
๐ Market Data
| Price | $5.37 |
|---|---|
| Volume | 316,807 |
| Market Cap | 65.79M |
| Beta | -0.770 |
| RSI (14-Day) | 48.0 |
| 200-Day MA | $4.93 |
| 50-Day MA | $6.48 |
| 52-Week High | $11.89 |
| 52-Week Low | $3.20 |
| Forward P/E | -3.69 |
| Price / Book | 15.52 |
๐ฏ Investment Strategy Scores
CING scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ช Falling Knife (54/100) โ this strategy Contrarian plays (oversold + below moving average).
Lowest fit among scored strategies: ๐ Institutional Whale (1/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find CING in your text
Paste any article, transcript, or post โ the tool will extract CING and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.